AG˹ٷ

STOCK TITAN

[Form 4] UNITEDHEALTH GROUP INCORPORATED (Delaware) Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.

  • Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
  • Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
  • No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.

The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.

La dichiarazione Form 4 per UnitedHealth Group (UNH) datata 02/07/2025 riporta la consueta remunerazione trimestrale in azioni per il direttore non esecutivo Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità azionarie differite (concessi immediatamente, devono essere mantenute fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in due trust aggiuntivi, per un totale indiretto di 2.246 azioni.
  • Non sono stati acquisiti né ceduti strumenti derivati; la dichiarazione indica che le assegnazioni rappresentano la normale remunerazione trimestrale del direttore, non basata su incentivi o acquisti di mercato.

La dichiarazione ha natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment degli insider oltre la consueta remunerazione del consiglio.

La presentación del Formulario 4 para UnitedHealth Group (UNH) con fecha 02/07/2025 revela la compensación trimestral habitual en acciones para el director no ejecutivo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (concedidas inmediatamente, deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones ordinarias, ambas otorgadas a costo cero.
  • Propiedad tras la transacción: 2,750 acciones ordinarias en propiedad directa; 2,146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, para un total indirecto de 2,246 acciones.
  • No se adquirieron ni vendieron valores derivados; la presentación indica que los premios son la compensación trimestral regular del director, no basada en incentivos ni en compras de mercado.

La presentación es de carácter administrativo, con sin impacto en las operaciones de la empresa, la estructura de capital o el sentimiento de los insiders más allá de la compensación habitual del consejo.

2025� 7� 2일자 UnitedHealth Group(UNH) Form 4 제출�� 비임� 이사 Paul R. Garcia� 대� 정기 분기� 주식 보상� 공개합니�.

  • 거래 내역 (2025� 7� 1�): 173개의 이연 주식 단위(즉시 권리 확정, 이사� 임기 종료 시까지 보유해야 �)와 96주의 보통주가 모두 무상으로 수여되었습니�.
  • 거래 � 보유 현황: 직접 보유� 보통� 2,750�; 취소 가능한 신탁� 2,146�; 추가 � � 신탁� 각각 45주와 55� 보유, � 간접 보유 주식은 2,246주입니다.
  • 파생 증권� 취득 또는 처분은 없었으며, 제출서에� � 보상� 인센티브 기반이나 시장 매입� 아닌 정기 분기� 이사 보상임을 명시하고 있습니다.

� 제출은 행정� 성격이며, 회사 운영, 자본 구조, 내부� 심리에는 관례적인 이사� 보상 외에 영향� 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle la rémunération trimestrielle habituelle en actions pour le directeur non exécutif Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d’actions différées (acquises immédiatement, doivent être conservées jusqu’� la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, soit une détention indirecte totale de 2 246 actions.
  • Aucun titre dérivé n’a été acquis ou cédé ; le dépôt précise que ces attributions correspondent à la rémunération trimestrielle régulière du directeur, non basée sur des incitations ou des achats sur le marché.

Le dépôt est de nature administrative, avec aucun impact sur les opérations de la société, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Form 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktienanteile (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide zu Nullkosten ä.
  • Besitz nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 indirekt gehaltene Aktien.
  • Es wurden keine derivativen Wertpapiere erworben oder veräußert; die Einreichung nennt die Zuteilungen als reguläre vierteljährliche Direktorenvergütung, nicht als leistungsabhängig oder marktbasierte Käufe.

Die Einreichung ist administrativer Natur, mit keiner Auswirkung auf den Geschäftsbetrieb, die Kapitalstruktur oder die Insiderstimmung über die übliche Vorstandsvergütung hinaus.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; neutral for valuation.

The reported acquisitions are standard board compensation—non-cash and immaterial relative to UNH’s 930 million shares outstanding. The director’s aggregate direct stake (�0.0003%) remains negligible, offering no meaningful signal of insider conviction or strategy shift. No derivatives, sales, or large block moves were disclosed, and there is no indication of upcoming corporate events. Consequently, the filing should be viewed as housekeeping rather than a catalyst.

TL;DR: Confirms UNH’s standard board pay structure; no red flags.

The grant aligns with prevailing S&P 500 director pay practice of quarterly stock/DSU awards to foster alignment with shareholders. Mandatory deferral of DSUs until board departure supports long-term oversight. No unusual acceleration clauses or special awards appear, indicating consistent, transparent governance. The filing poses no governance concerns and is non-impactful to investors.

La dichiarazione Form 4 per UnitedHealth Group (UNH) datata 02/07/2025 riporta la consueta remunerazione trimestrale in azioni per il direttore non esecutivo Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità azionarie differite (concessi immediatamente, devono essere mantenute fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in due trust aggiuntivi, per un totale indiretto di 2.246 azioni.
  • Non sono stati acquisiti né ceduti strumenti derivati; la dichiarazione indica che le assegnazioni rappresentano la normale remunerazione trimestrale del direttore, non basata su incentivi o acquisti di mercato.

La dichiarazione ha natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment degli insider oltre la consueta remunerazione del consiglio.

La presentación del Formulario 4 para UnitedHealth Group (UNH) con fecha 02/07/2025 revela la compensación trimestral habitual en acciones para el director no ejecutivo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (concedidas inmediatamente, deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones ordinarias, ambas otorgadas a costo cero.
  • Propiedad tras la transacción: 2,750 acciones ordinarias en propiedad directa; 2,146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, para un total indirecto de 2,246 acciones.
  • No se adquirieron ni vendieron valores derivados; la presentación indica que los premios son la compensación trimestral regular del director, no basada en incentivos ni en compras de mercado.

La presentación es de carácter administrativo, con sin impacto en las operaciones de la empresa, la estructura de capital o el sentimiento de los insiders más allá de la compensación habitual del consejo.

2025� 7� 2일자 UnitedHealth Group(UNH) Form 4 제출�� 비임� 이사 Paul R. Garcia� 대� 정기 분기� 주식 보상� 공개합니�.

  • 거래 내역 (2025� 7� 1�): 173개의 이연 주식 단위(즉시 권리 확정, 이사� 임기 종료 시까지 보유해야 �)와 96주의 보통주가 모두 무상으로 수여되었습니�.
  • 거래 � 보유 현황: 직접 보유� 보통� 2,750�; 취소 가능한 신탁� 2,146�; 추가 � � 신탁� 각각 45주와 55� 보유, � 간접 보유 주식은 2,246주입니다.
  • 파생 증권� 취득 또는 처분은 없었으며, 제출서에� � 보상� 인센티브 기반이나 시장 매입� 아닌 정기 분기� 이사 보상임을 명시하고 있습니다.

� 제출은 행정� 성격이며, 회사 운영, 자본 구조, 내부� 심리에는 관례적인 이사� 보상 외에 영향� 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle la rémunération trimestrielle habituelle en actions pour le directeur non exécutif Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d’actions différées (acquises immédiatement, doivent être conservées jusqu’� la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, soit une détention indirecte totale de 2 246 actions.
  • Aucun titre dérivé n’a été acquis ou cédé ; le dépôt précise que ces attributions correspondent à la rémunération trimestrielle régulière du directeur, non basée sur des incitations ou des achats sur le marché.

Le dépôt est de nature administrative, avec aucun impact sur les opérations de la société, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Form 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktienanteile (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide zu Nullkosten ä.
  • Besitz nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 indirekt gehaltene Aktien.
  • Es wurden keine derivativen Wertpapiere erworben oder veräußert; die Einreichung nennt die Zuteilungen als reguläre vierteljährliche Direktorenvergütung, nicht als leistungsabhängig oder marktbasierte Käufe.

Die Einreichung ist administrativer Natur, mit keiner Auswirkung auf den Geschäftsbetrieb, die Kapitalstruktur oder die Insiderstimmung über die übliche Vorstandsvergütung hinaus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GARCIA PAUL R

(Last) (First) (Middle)
C/O UNITEDHEALTH GROUP INCORPORATED
1 HEALTH DRIVE

(Street)
EDEN PRAIRIE MN 55344

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITEDHEALTH GROUP INC [ UNH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 173(1) A $0 2,654 D
Common Stock 07/01/2025 A 96(2) A $0 2,750 D
Common Stock 2,146 I By Revocable Trust
Common Stock 45 I By Trust 2
Common Stock 55 I By Trust 3
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents deferred stock units that are granted as regular quarterly compensation for service as a director of UnitedHealth Group. Deferred stock units are immediately vested, but must be retained by the director until the director's completion of service on the Board.
2. Represents shares of common stock that are granted as regular quarterly compensation for service as a director of UnitedHealth Group.
Remarks:
Faraz A. Choudhry, Attorney-in-Fact for Paul R. Garcia 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group shares did Paul R. Garcia acquire on 07/01/2025?

He received 96 shares of common stock and 173 deferred stock units as part of quarterly board compensation.

What is Paul R. Garcia’s total direct ownership in UNH after the transaction?

Following the award, he directly holds 2,750 common shares of UnitedHealth Group.

Are the deferred stock units (DSUs) immediately vested?

Yes. The DSUs vest immediately but must be held until the director’s service on the board ends.

Did the filing disclose any insider sales or derivative transactions?

No. The Form 4 reports only acquisitions of stock and DSUs; no sales or derivative activity were reported.

Does this Form 4 filing affect UnitedHealth Group’s share count?

No. The awards are sourced from the company’s existing equity compensation plan and do not materially alter the total shares outstanding.
Unitedhealth Gp

NYSE:UNH

UNH Rankings

UNH Latest News

UNH Latest SEC Filings

UNH Stock Data

265.35B
904.35M
0.24%
90.3%
0.95%
Healthcare Plans
Hospital & Medical Service Plans
United States
EDEN PRAIRIE